Which of the following best describes an illusion?

A. Only engages in solitary activities. Individuals with schizoid personality disorder (SPD) prefer solitary activities and show little interest in social interactions. They are emotionally detached and lack the desire for close relationships, including friendships and romantic partnerships.

B. Dislikes criticism. While people with SPD may be indifferent to praise or criticism, they are not particularly sensitive to it. Unlike avoidant personality disorder, where individuals avoid social interactions due to fear of rejection, those with SPD are emotionally detached and often indifferent to others' opinions.

C. Always wants to be center of attention. This describes histrionic personality disorder (HPD), not schizoid personality disorder. Individuals with HPD seek constant attention, approval, and validation, whereas those with SPD prefer to remain isolated and avoid social engagement.

D. Affective flattening. Affective flattening (emotional coldness or limited emotional expression) is a key feature of SPD. Individuals display minimal facial expressions, monotone speech, and reduced nonverbal communication, contributing to their perceived social aloofness.

A. Haloperidol (Haldol) is a first-generation (typical) antipsychotic, which has a higher risk of extrapyramidal symptoms (EPS) but a lower risk of metabolic syndrome compared to second-generation antipsychotics.

B. Aripiprazole (Abilify) is a second-generation (atypical) antipsychotic with a lower risk of metabolic side effects. It has a partial dopamine agonist mechanism, which makes it less likely to cause weight gain, dyslipidemia, or glucose intolerance.

C. Clozapine (Clozaril) has the highest risk of metabolic syndrome among antipsychotics. It is associated with significant weight gain, hyperglycemia, dyslipidemia, and an increased risk of diabetes. Regular metabolic monitoring (weight, blood glucose, lipids) is essential for patients taking clozapine.

D. Lurasidone (Latuda) is a second-generation antipsychotic with a lower metabolic risk compared to other atypical antipsychotics. It is generally considered weight-neutral and has minimal effects on glucose and lipid metabolism.